These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32233616)

  • 1. Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial.
    Hennessy MA; Morris PG
    Ann Palliat Med; 2020 Mar; 9(2):504-509. PubMed ID: 32233616
    [No Abstract]   [Full Text] [Related]  

  • 2. Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment.
    Arecco L; Blondeaux E; Damassi A; Fregatti P; Lambertini M
    Ann Palliat Med; 2020 Mar; 9(2):512-516. PubMed ID: 32233615
    [No Abstract]   [Full Text] [Related]  

  • 3. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment of patients with early breast cancer: recent updates and state of the art.
    Caparica R; Brandão M; Piccart M
    Breast; 2019 Nov; 48 Suppl 1():S7-S20. PubMed ID: 31839166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Tesch ME; Gelmon KA
    Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
    Saad ED; Squifflet P; Burzykowski T; Quinaux E; Delaloge S; Mavroudis D; Perez E; Piccart-Gebhart M; Schneider BP; Slamon D; Wolmark N; Buyse M
    Lancet Oncol; 2019 Mar; 20(3):361-370. PubMed ID: 30709633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine: a game changer in HER2-positive early breast cancer.
    Mano M
    Future Oncol; 2020 Nov; 16(32):2595-2609. PubMed ID: 32734779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ado-trastuzumab emtansine in current clinical practice.
    Turshudzhyan A
    J Oncol Pharm Pract; 2021 Jan; 27(1):150-155. PubMed ID: 32838683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 testing in patients with breast cancer.
    Dixon JM; Wilson V; Verrill M; Symmans WF
    BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887
    [No Abstract]   [Full Text] [Related]  

  • 11. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term.
    Jankowitz RC; Brufsky AM
    Breast Cancer Res; 2012 Apr; 14(2):308. PubMed ID: 22546039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial.
    Khattak MN; Chichura AM; Lang JE
    Ann Surg Oncol; 2024 Mar; 31(3):1423-1427. PubMed ID: 38127215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.
    Gradishar WJ
    Ann Oncol; 2013 Oct; 24(10):2492-2500. PubMed ID: 23827380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine.
    Hopkins AM; Rowland A; Logan JM; Sorich MJ
    Breast; 2019 Aug; 46():90-94. PubMed ID: 31170589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
    Okines AF
    Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.